These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28539529)

  • 1. Membrane Trafficking Illuminates a Path to Parkinson's Disease.
    Hasegawa T; Sugeno N; Kikuchi A; Baba T; Aoki M
    Tohoku J Exp Med; 2017 May; 242(1):63-76. PubMed ID: 28539529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein Trafficking in Parkinson's Disease: Insights From Fly and Mouse Models.
    Cheng J; Lu Q; Song L; Ho MS
    ASN Neuro; 2018; 10():1759091418812587. PubMed ID: 30482039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein and dopamine at the crossroads of Parkinson's disease.
    Venda LL; Cragg SJ; Buchman VL; Wade-Martins R
    Trends Neurosci; 2010 Dec; 33(12):559-68. PubMed ID: 20961626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease.
    Vargas JY; Grudina C; Zurzolo C
    Ageing Res Rev; 2019 Mar; 50():89-101. PubMed ID: 30690184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Targeting Transcellular Transport of α-Synuclein for Developing Disease-Modifying Therapies for Synucleinopathy].
    Hasegawa T
    Brain Nerve; 2018 May; 70(5):551-556. PubMed ID: 29760292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
    Benskey MJ; Perez RG; Manfredsson FP
    J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
    Pozo Devoto VM; Falzone TL
    Dis Model Mech; 2017 Sep; 10(9):1075-1087. PubMed ID: 28883016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids: Key Players That Modulate α-Synuclein Toxicity and Neurodegeneration in Parkinson's Disease.
    Mori A; Imai Y; Hattori N
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease.
    O'Keeffe GW; Sullivan AM
    Parkinsonism Relat Disord; 2018 Nov; 56():9-15. PubMed ID: 29934196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Contribution of
    Longhena F; Faustini G; Missale C; Pizzi M; Spano P; Bellucci A
    Neural Plast; 2017; 2017():5012129. PubMed ID: 28133550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF-derived extracellular vesicles from patients with Parkinson's disease induce symptoms and pathology.
    Herman S; Djaldetti R; Mollenhauer B; Offen D
    Brain; 2023 Jan; 146(1):209-224. PubMed ID: 35881523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
    Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein-carrying extracellular vesicles in Parkinson's disease: deadly transmitters.
    Chistiakov DA; Chistiakov AA
    Acta Neurol Belg; 2017 Mar; 117(1):43-51. PubMed ID: 27473175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synaptic failure and α-synuclein.
    Calo L; Wegrzynowicz M; Santivañez-Perez J; Grazia Spillantini M
    Mov Disord; 2016 Feb; 31(2):169-77. PubMed ID: 26790375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
    Xu S; Chan P
    Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.